2:50 PM
 | 
Jan 05, 2018
 |  BioCentury  |  Emerging Company Profile

Against radical pain

How CerSci’s non-opioids could treat acute pain and prevent chronic pain

CerSci Therapeutics thinks that by neutralizing peroxynitrite and other free radicals it can treat acute pain and prevent it from becoming chronic, without the potential for abuse and addiction.

CerSci was founded in 2014 to create non-opioid pain drugs, and acquired its lead candidate, CT-044, two years later from Galleon Pharmaceuticals Inc. CerSci co-founder and CSO Scott Dax was previously chief technology officer at Galleon.

The molecule had been identified by Dax while he was at Galleon, which was focused on developing non-opioid molecules to prevent respiratory distress following surgery in patients with a history of sleep apnea. However, CT-044 did not show an effect on breathing control. It did show a benefit in preclinical efficacy models for pain, an indication outside Galleon’s focus.

According to Dax, in response to cellular injury, cells produce free radicals that trigger release of proinflammatory and pronociceptive prostaglandins. Both types of signals...

Read the full 722 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >